Kaken Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3207000005
JPY
3,910.00
45 (1.16%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
Net Sales
94,035.00
72,044.00
72,984.00
76,034.00
74,979.00
89,234.00
94,167.00
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
94,035.00
72,044.00
72,984.00
76,034.00
74,979.00
89,234.00
94,167.00
Raw Material Cost
35,773.00
33,822.00
33,719.00
34,716.00
34,300.00
38,984.00
40,590.00
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
28.00
17.00
17.00
17.00
17.00
17.00
17.00
Selling and Distribution Expenses
18,501.00
16,165.00
15,476.00
15,833.00
16,155.00
17,320.00
18,724.00
Other Expenses
1,869.70
1,252.60
1,577.20
840.30
671.90
640.10
1,024.40
Total Expenditure (Excl Depreciation)
72,999.00
62,530.00
64,984.00
58,969.00
57,191.00
62,722.00
69,575.00
Operating Profit (PBDIT) excl Other Income
21036
9514
8000
17065
17788
26512
24592
Other Income
455.00
321.00
699.00
601.00
890.00
410.00
359.00
Operating Profit (PBDIT)
24,045.00
12,588.00
11,267.00
20,147.00
20,996.00
29,683.00
27,550.00
Interest
28.00
17.00
17.00
17.00
17.00
17.00
17.00
Exceptional Items
-2,025.00
-19.00
-1,863.00
-3,763.00
-5.00
-312.00
-10.00
Gross Profit (PBDT)
58,262.00
38,222.00
39,265.00
41,318.00
40,679.00
50,250.00
53,577.00
Depreciation
2,554.00
2,753.00
2,568.00
2,481.00
2,318.00
2,761.00
2,599.00
Profit Before Tax
19,435.00
9,796.00
6,817.00
13,885.00
18,657.00
26,592.00
24,922.00
Tax
5,490.00
1,770.00
1,377.00
4,336.00
5,252.00
7,222.00
7,147.00
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
13,945.00
8,025.00
5,440.00
9,549.00
13,405.00
19,370.00
17,775.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
13,945.00
8,025.00
5,440.00
9,549.00
13,405.00
19,370.00
17,775.00
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
13,945.00
8,025.00
5,440.00
9,549.00
13,405.00
19,370.00
17,775.00
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
1,52,634.00
1,43,755.00
1,36,258.00
1,37,747.00
1,36,257.00
1,28,468.00
1,21,131.00
Earnings per share (EPS)
365.42
212.66
144.79
251.44
347.37
494.89
445.78
Diluted Earnings per share
365.42
212.66
144.79
251.44
347.37
494.89
445.78
Operating Profit Margin (Excl OI)
22.37%
13.21%
10.96%
22.44%
23.72%
29.71%
26.12%
Gross Profit Margin
23.38%
17.42%
12.86%
21.52%
27.97%
32.89%
29.23%
PAT Margin
14.83%
11.14%
7.45%
12.56%
17.88%
21.71%
18.88%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 30.52% vs -1.29% in Mar 2024

stock-summary

Consolidate Net Profit

YoY Growth in year ended Mar 2025 is 73.77% vs 47.52% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 92.30% vs 16.08% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 64.71% vs 0.00% in Mar 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Mar 2025 has improved from Mar 2024

Compare Annual Results Of Kaken Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(JPY)
Change(%)
Net Sales
94,035.00
33,072.00
60,963.00
184.33%
Other Operating Income
0.00
0.00
0.00
Total Operating income
94,035.00
33,072.00
60,963.00
184.33%
Raw Material Cost
35,773.00
11,524.00
24,249.00
210.42%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
28.00
155.00
-127.00
-81.94%
Selling and Distribution Expenses
18,501.00
12,958.00
5,543.00
42.78%
Other Expenses
1,869.70
1,527.60
342.10
22.39%
Total Expenditure (Excl Depreciation)
72,999.00
39,913.00
33,086.00
82.90%
Operating Profit (PBDIT) excl Other Income
21,036.00
-6,841.00
27,877.00
407.50%
Other Income
455.00
-482.00
937.00
194.40%
Operating Profit (PBDIT)
24,045.00
-3,949.00
27,994.00
708.89%
Interest
28.00
155.00
-127.00
-81.94%
Exceptional Items
-2,025.00
1,064.00
-3,089.00
-290.32%
Gross Profit (PBDT)
58,262.00
21,548.00
36,714.00
170.38%
Depreciation
2,554.00
3,374.00
-820.00
-24.30%
Profit Before Tax
19,435.00
-6,414.00
25,849.00
403.01%
Tax
5,490.00
-1,718.00
7,208.00
419.56%
Provisions and contingencies
0
0
0.00
Profit After Tax
13,945.00
-4,758.00
18,703.00
393.09%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
13,945.00
-4,758.00
18,703.00
393.09%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
63.00
-63.00
-100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
13,945.00
-4,695.00
18,640.00
397.02%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
1,52,634.00
47,043.00
1,05,591.00
224.46%
Earnings per share (EPS)
365.42
-38.43
403.85
1,050.87%
Diluted Earnings per share
365.42
-38.43
403.85
1,050.87%
Operating Profit Margin (Excl OI)
22.37%
-20.69%
0.00
43.06%
Gross Profit Margin
23.38%
-9.19%
0.00
32.57%
PAT Margin
14.83%
-14.39%
0.00
29.22%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 9,403.50 Million
in Mar 2025

Figures in Million
stock-summary

YoY Growth in year ended Mar 2025 is 30.52% vs -1.29% in Mar 2024

Annual - Consolidate Net Profit
Consolidate Net Profit 1,394.50 Million
in Mar 2025

Figures in Million
stock-summary

YoY Growth in year ended Mar 2025 is 73.77% vs 47.52% in Mar 2024

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 2,359.00 Million
in Mar 2025

Figures in Million
stock-summary

YoY Growth in year ended Mar 2025 is 92.30% vs 16.08% in Mar 2024

Annual - Interest
Interest 2.80 Million
in Mar 2025

Figures in Million
stock-summary

YoY Growth in year ended Mar 2025 is 64.71% vs 0.00% in Mar 2024

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 22.37%
in Mar 2025

Figures in %
stock-summary

YoY Growth in year ended Mar 2025 has improved from Mar 2024